Free tool
FAERS Monitor: Chorionic Gonadotropin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 017067 or its brand name (Chorionic Gonadotropin, Gonadotropin, Chorionic). Reports on generic versions are filed under their own applications.
Reports
561
Serious
417
74% of reports
Hospitalization
254
Death reported
26
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- ovarian hyperstimulation syndrome130
- drug ineffective38
- drug exposure during pregnancy37
- off label use33
- ascites31
- ectopic pregnancy31
- dyspnoea27
- nausea27
- headache26
- abdominal distension25
- pain24
- pleural effusion24
- abortion spontaneous23
- abdominal pain21
- caesarean section19
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 9 |
| 2005 | 27 |
| 2006 | 27 |
| 2007 | 45 |
| 2008 | 18 |
| 2009 | 29 |
| 2010 | 26 |
| 2011 | 53 |
| 2012 | 78 |
| 2013 | 14 |
| 2014 | 15 |
| 2015 | 5 |
| 2016 | 27 |
| 2017 | 16 |
| 2018 | 20 |
| 2019 | 20 |
| 2020 | 24 |
| 2021 | 20 |
| 2022 | 27 |
| 2023 | 17 |
| 2024 | 16 |
| 2025 | 10 |
| 2026 | 18 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,598 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ovarian hyperstimulation syndromeSignal | 130 | 2214.6 | 1894.0 | 269,552 |
| ectopic pregnancySignal | 31 | 381.8 | 270.7 | 11,283 |
| caesarean sectionSignal | 19 | 61.3 | 39.4 | 1,066 |
| drug exposure during pregnancySignal | 37 | 40.8 | 29.9 | 1,399 |
| ascitesSignal | 31 | 39.6 | 28.1 | 1,128 |
| abortion spontaneousSignal | 23 | 21.5 | 14.4 | 431 |
| pleural effusionSignal | 24 | 14.8 | 10.0 | 296 |
| abdominal distensionSignal | 25 | 9.0 | 6.1 | 170 |
| abdominal painSignal | 21 | 3.4 | 2.2 | 33 |
| dyspnoea | 27 | 1.8 | 1.2 | 9 |
| headache | 26 | 1.6 | 1.1 | 5 |
| pain | 24 | 1.5 | 1.0 | 3 |
| off label use | 33 | 1.4 | 1.0 | 4 |
| nausea | 27 | 1.3 | 0.9 | 1 |
| drug ineffective | 38 | 1.1 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.